Forest Labs Starts Patent Battle Over Beta-Blocker
Pharmaceutical maker Forest Laboratories Inc. on Wednesday accused a slew of generics makers of violating its patent for beta-blocker Bystolic in a complaint filed in Delaware federal court....To view the full article, register now.
Already a subscriber? Click here to view full article